|
 |
|
|
Jeongmin Kim, Ph.D.
|
|
Chief Executive Officer & Founder
|
|
|
|
Jeongmin Kim, CEO of DigmBio, is a distinguished authority in the realm of small molecules, acclaimed for his prolific career in pioneering new drug R&D endeavors across esteemed Korean pharmaceutical entities like LG Chemical, Green Cross Biopharma, and Jeil Pharmaceutical Co. With an extensive background spanning decades in cancer therapy and CNS diseases, notably in PARP inhibitors, Jeongmin brings unparalleled expertise to the forefront. Holding a Ph.D. in biochemistry from the University of Wisconsin-Madison, his leadership is poised to drive DigmBio towards groundbreaking advancements in medical innovation.
|
|
|
 |
|
|
Jae-Hoon Kang Ph.D
|
|
Chief Technology Officer
|
|
|
|
Jae-Hoon Kang assumes the role of Chief Technology Officer, leading pharmaceutical development and manufacturing endeavors at DigmBio. Prior to joining the company, Jae-Hoon previously served as Chief Executive Officer at Ildong Hyaltech, and the head of R&D at Ildong Pharmaceutical Co, a firm specializing in cancer therapies and antibiotics. Jae-Hoon is revered for his profound expertise in new drug R&D and global clinical trials, having been entrusted as a key committee member in reviewing and deciding on government grants and assistance for new drug R&D initiatives over decades. He earned his Ph.D. in chemistry from Sungkyunkwan University.
|
|
|
 |
|
|
Jung-Ho Kim Ph.D.
|
|
Chief Scientific Officer
|
|
|
|
Jung-Ho Kim serves as the Chief Scientific Officer, leading new drug development at DigmBio. Renowned for his pivotal role in developing and out-licensing Lazertinib to Yuhan during his tenure as CSO at Oscotec, alongside his colleagues, Dr. Kim has demonstrated exceptional leadership. Lazertinib was finally licensed to Janssen, a pharmaceutical company of Johnson and Johnson, with FDA approval pending following the completion of the global phase 3 clinical trial, Mariposa, targeting non-small cell lung cancer treatment. With extensive expertise in discovering and developing kinase inhibitors like Cevidoplenib, Denfivontinib, and Lazertinib, Jung-Ho Kim has made significant contributions to the field. He earned his Ph.D. in chemistry from the University of Illinois at Urbana-Champaign.
|
|
|
 |
|
|
Myung-Eun Jung Ph.D.
|
|
Managing Director, Head of Bio Division
|
|
|
|
Myung-Eun Jung leads as Head of the Bio Division at DigmBio, overseeing the research and development for new drug candidates. With a robust background, Myung-Eun previously contributed her expertise at Green Cross Biopharma for about 15 years. During her tenure, she held exclusive leadership roles and spearheaded various R&D initiatives, spanning small molecule, vaccines, plasma derivatives, and antibody therapies. Her comprehensive experience encompasses global clinical trials and regulatory approvals. Myung-Eun earned her Ph.D. in Neuroscience from Hallym University .
|
|
|
 |
|
|
Eunwoo Jeon
|
|
Chief Business Officer
|
|
|
|
Eunwoo serves as the Chief Business Officer at DigmBio, overseeing the global commercialization efforts for the company's new drugs and partnerships. Prior to joining DigmBio, he accumulated valuable experience working for a Korean merchant bank, the corporate recovery group at KPMG in the U.S., and Golden Compass Advisors, a boutique advisory firm specializing in cross-border transactions. Eunwoo is highly regarded as a senior investment professional, recognized for his extensive international experience in mergers & acquisitions, restructuring, and business consultancy and advisement. With a proven track record of success, he has effectively managed a diverse range of projects and transactions for corporate clients and institutional investors. Eunwoo holds an MBA from Duke University.
|
|
|
 |
|
|
Seong-Ryong Hwang
|
|
Chief Financial Officer
|
|
|
|
Seong-Ryong Hwang assumes the role of Chief Financial Officer at DigmBio, bringing over 34 years of experiences in finance and investment from Daewoo securities (Miraeasset securities), a prominent Korean securities firm. With expertise in equity underwriting and a CFA charter obtained in 2002, he brings a robust background in investment analysis and capital market operations, enriched by practical experience. Mr. Hwang, as CFO, is committed to bolstering the company's financial framework, with a particular emphasis on capital acquisition and strategic financial planning. He holds a Master's degree in English literature from Seoul National University.
|
|
